The platelet-derived growth factor C (PDGFC) antibody is a crucial tool in studying the biological functions and pathological roles of the PDGFC protein, a member of the PDGF family. PDGFC, a secreted glycoprotein, binds to the PDGFRα and PDGFRαα homodimers, activating downstream signaling pathways involved in cell proliferation, migration, and survival. Unlike other PDGF isoforms, PDGFC is synthesized as an inactive precursor requiring proteolytic cleavage for activation. It plays vital roles in embryonic development, tissue repair, and angiogenesis but is also implicated in diseases such as fibrosis, atherosclerosis, and cancer, where its overexpression correlates with tumor progression, metastasis, and stromal activation.
PDGFC antibodies are widely used in research to detect and quantify PDGFC expression in tissues or cell lysates via techniques like Western blotting, immunohistochemistry, and ELISA. They aid in elucidating PDGFC's interaction with receptors, its activation mechanisms, and its contribution to disease pathways. Therapeutic applications are also explored, as inhibiting PDGFC signaling using neutralizing antibodies or small molecules shows potential in preclinical models of cancer and fibrotic disorders. However, challenges remain in understanding its context-dependent roles and optimizing targeted therapies. Overall, PDGFC antibodies serve as essential reagents for both basic research and translational studies aiming to modulate PDGF signaling in disease.